Stay in the know
We’ll send you the latest insights and briefings tailored to your needs
28 Jun 2024
Insight
In this conversation, HSF Co-Head of Venture and Growth Capital, Dylan Doran Kennett, speaks with Bedford Transearch's Director for North America Life Sciences, Darren Raycroft, on the topic of helping Life Sciences companies land and expand globally. The conversation unpicks key trends and considerations for innovative companies entering new markets in the US, UK and EMEA, including:
- The market outlook for 2024/5
- Equity financing trends and IPO activity
- Access to capital
- Executive talent and recruitment trends in the US
How we can support you
We know that life science and pharma startups are at the forefront of innovation, driving advancements in biotechnology, pharmaceuticals, medical devices, and health tech. Navigating the complexities of this dynamic sector requires not only scientific acumen but also robust legal support tailored to the unique challenges faced by early-stage companies. We provide an end-to-end legal capability across the globe ensuring that you thrive in this competitive landscape. Our legal advice ranges from crucial advice to protect your intellectual property, guidance to navigate stringent life sciences regulatory requirements, tailored and strategic funding and investment legal advice and more.
We have a leading and well-established international venture and growth capital team, ranked in the latest edition of Legal 500 UK 2024. Our team delivers the full spectrum of venture and growth transactions, from seed, Series A and beyond, all the way to Exit. We have a blended practice acting for companies and investors, including VC and PE firms, sovereign and institutional investors, investment banks and corporate venture funds, giving us a clear view of the market practice for key transaction terms. Our venture and growth capital team has specific experience advising life science and pharma companies on fundraising, global expansion and eventual exits.
Our work
|
Axa Investment Managers, Adjuvant Capital and Novo Holdings on their $37m Series A investment in LimmaTech Biologics, a clinical stage biopharmaceutical company based in Switzerland |
|
ImmVirX on its AUD$22 million capital raising |
|
Goldman Sachs Asset Management on its investment in Aragen Lifesciences and Biocon Biologics |
|
Pfizer Ventures, on a number of Series A and B rounds in UK life sciences companies, including, Artios, Nucleome, Grey Wolf Therapeutics, Storm Therapeutics, T-Rex Bio and Zura Bio* *Experience prior to joining Herbert Smith Freehills |
|
Grok Ventures on its investment in Juvenescence’s $100 million Series B round |
|
Phytome Life Sciences on all matters relating to its fundraising and commercialisation strategy.* *Experience prior to joining Herbert Smith Freehills |
Key contacts
Legal Notice
The contents of this publication are for reference purposes only and may not be current as at the date of accessing this publication. They do not constitute legal advice and should not be relied upon as such. Specific legal advice about your specific circumstances should always be sought separately before taking any action based on this publication.
© Herbert Smith Freehills 2024